ACME UNITED CORP - 10-Q Summary (Period Ended Sep 30, 1996)
Business Context and Reporting Period
This is a quarterly report (Form 10-Q) for ACME UNITED CORPORATION for the period ended September 30, 1996. The company operates in domestic consumer products (first aid, rulers), medical products, and foreign operations. The reporting period covers the third quarter and the first nine months of 1996, with comparative data from 1995.
Key Financial Metrics
| Metric | Q3 1996 | Q3 1995 | 9M 1996 | 9M 1995 |
|---|---|---|---|---|
| Net Sales ($000s) | 13,281 | 13,838 | 38,103 | 41,205 |
| Gross Profit Margin | 26.2% | 27.6% | 23.6% | 28.2% |
| Net Income (Loss) ($000s) | (485) | (166) | (2,540) | 7 |
| EPS ($) | (0.15) | (0.05) | (0.76) | 0.00 |
| Cash from Operations ($000s) | N/A | N/A | 1,058 | (1,413) |
| Total Debt ($000s) | 16,505 | N/A | 16,505 | N/A |
| Working Capital ($000s) | 11,121 | N/A | 11,121 | 15,975 |
Note: Total Debt is the sum of Notes payable due within one year ($3,511) and Long term debt ($12,994). Working Capital is Current Assets ($20,855) minus Current Liabilities ($9,734).
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 4% in Q3 and 7% for the nine months ended Sep 30, 1996. A significant portion of this decline ($2.6M for 9M) is attributed to the divestiture of the Altenbach business in Germany.
- Segment Performance: Domestic Consumer sales grew 20% in Q3 (driven by first aid and ruler lines). Medical product sales declined due to volume drops in the low-margin custom tray market. Foreign sales (excluding Altenbach) were relatively flat.
- Profitability: The company reported a net loss for both Q3 and the nine-month period, compared to a net loss in Q3 1995 and a negligible profit in 9M 1995. Gross margins compressed due to excess capacity and restructuring costs.
- Balance Sheet: Total assets decreased from $37.0M to $29.8M. Inventory levels dropped significantly by 45% (excluding Altenbach) as part of a reduction strategy. Total debt decreased by 21% compared to the prior year.
Guidance, Outlook, and Risks
- Restructuring Costs: The company incurred $580,000 in severance and $99,000 in restructuring costs in Q3. For the nine months, these totaled $869,000 and $926,000 respectively. Excluding these and the Altenbach loss, the company reported a continuing business profit in Q3 ($194,000) but a loss for the nine months ($474,000).
- Liquidity Strategy: Management emphasizes reducing inventory, debt, and interest expense. Future debt reduction is expected to be funded by inventory liquidation and operating cash flow.
- Credit Facilities: The U.S. subsidiary has a $13M revolving line of credit (expires May 1998) with $11.1M available. Foreign subsidiaries utilize overdraft arrangements expiring in 1996.
- Future Outlook: A new contract to supply disposable medical instruments to the Asian market is expected to generate sales beginning in Q4 1996.
- Risks: The filing notes that results for the nine months are not necessarily indicative of full-year results. Risks include soft sales in the UK and Germany and the impact of excess manufacturing capacity.
Investor Verification Checklist
- Verify the extent of the Altenbach divestiture impact on future revenue streams.
- Confirm the sustainability of the 20% growth in Domestic Consumer sales (first aid/rulers).
- Assess the timeline for the new Asian medical instrument contract to offset medical product declines.
- Monitor the effectiveness of inventory reduction strategies on cash flow generation.
- Review the status of foreign subsidiary overdraft arrangements expiring in 1996.